Quantcast

Latest Northwest Biotherapeutics Stories

2014-07-09 20:22:36

NEW YORK, July 9, 2014 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Northwest Biotherapeutics, Inc. ("Northwest Bio" or the "Company") (NasdaqCM: NWBO) in connection with possible breaches of federal securities laws. The investigation regards concerns that the Company made misleading statements regarding its clinical trial for DC-Vax Direct, its experimental cancer vaccine. http://photos.prnewswire.com/prnvar/20120409/MM84375LOGO To get more information, click here:...

2014-06-11 08:29:54

All 9 Out Of 9 Patients Who Have Reached 4 Injections Are Showing Tumor Cell Death, Tumor Shrinkage And/Or Stabilization Of Disease BETHESDA, Md., June 11, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that, in the ongoing Phase I/II clinical trial of DCVax-Direct for all types of inoperable solid tumors, all 9 out of 9 patients who have...

2014-06-10 08:31:06

First Site Opened In Late May, 7 More Sites Now Scheduled During June and July BETHESDA, Md., June 10, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has initiated the Phase III trial of DCVax-L in Germany. The first site to open in Germany was a medical center in Dresden, which was initiated in late May. The Company has now scheduled the...

2014-06-04 12:29:56

BETHESDA, Md., June 4, 2014 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Linda F. Powers, CEO, will present at the Jefferies 2014 Global Healthcare Conference, which is being held in New York. http://photos.prnewswire.com/prnvar/20110329/SF73084LOGO NW Bio's presentation will take place on Wednesday, June 4, at 2:00 p.m. EDT in Ballroom 5 at the...

2014-05-29 08:30:55

Company Reported Positive Preliminary Responses in Phase I/II Trial Patients; Feuerstein Falsely Claims There Is No Positive Trial Information BETHESDA, Md., May 29, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, refuted the latest blatantly false and misleading statements made by Adam Feuerstein, in an article on Tuesday, May 27....

2014-05-27 12:32:49

BETHESDA, Md., May 27, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio) announced today that the Company will host a conference call and webcast with CEO Linda Powers today, May 27, 2014, at 4:30 p.m. Eastern time to review the early results of the Phase I/II DCVax®-Direct Trial announced this morning and answer questions. http://photos.prnewswire.com/prnvar/20110329/SF73084LOGO Participants must register in order to participate in the conference call. There are...

2014-05-27 08:29:27

Initial Responses Seen Before Patients Have Completed Treatments; BETHESDA, Md., May 27, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided a summary of initial data to date in its ongoing Phase I/II clinical trial of DCVax-Direct for all types of inoperable solid tumors. The Company reported that over 50% of the patients who have completed at least half of...

2014-05-15 08:32:30

First Case Study Announced While Broader Data Being Collected; Evidence Indicates Substantial Tumor Necrosis and Initial Tumor Regression BETHESDA, Md., May 15, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided an initial patient case study, showing signs of tumor necrosis (tumor death) and initial tumor regression, from the Company's ongoing...

2014-04-15 12:30:48

Major Production Increase Being Undertaken To Meet Growing Demand BETHESDA, Md., April 15, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of the first $15 million funding by a single institutional investor of the registered direct placement of up to $32 million which was announced by the Company last week. These first 2.27 million...

2014-04-07 08:31:07

Company Corrects His False Claims About Annual Report and Phase III Trial BETHESDA, Md., April 7, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today again set the record straight: Adam Feuerstein's latest, sensationalized headline claims about the Company's annual report and Phase III trial are once again factually wrong and materially misleading....


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related